Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain

Journal of Neurochemistry

Volumn 85, Issue 3, 2003, Pages 690-696

  Bosetti, Francesca ^a   Weerasinghe, Gayani R ^a   Rosenberger, Thad A ^a   Rapoport, Stanley I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Arachidonic acid; Bipolar disorder; Brain; Cyclooxygenase; Prostaglandin; Valproic acid

Indexed keywords

11 OXOTHROMBOXANE B2; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BRAIN PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ICOSANOID; LEUKOTRIENE B4; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; BRAIN LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ICOSANOID METABOLISM; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0038673579     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01701.x     Document Type: Article

References (57)

1. 2+-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J. Biol. Chem. 270, 445-450.
2. Basu-Modak S., Braissant O., Escher P., Desvergne B., Honegger P. and Wahli W. (1999) Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. J. Biol. Chem. 274, 35881-35888.
3. Becker C. M. and Harris R. A. (1983) Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch. Biochem. Biophys. 223, 381-392.
4. Bennett C. N. and Horrobin D. F. (2000) Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update. Prostaglandins Leukot. Essent. Fatty Acids 63, 47-59.
5. Bernard N., Sacquet J., Benzoni D. and Sassard J. (2000) Cyclooxygenases 1 and 2 and thromboxane synthase in kidneys of Lyon hypertensive rats. Am. J. Hypertens. 13, 404-409.
6. Bosetti F., Rintala J., Seemann R., Rosenberger T. A., Contreras M. A., Rapoport S. I. and Chang M. C. (2002a) Chronic lithium down-regulates cyclooxygenase-2 activity and prostaglandin E2 concentration in rat brain. Mol. Psychiatry 7, 844-849.
7. Bosetti F., Seemann R., Bell J. M., Zahorchak R., Friedman E., Rapoport S. I. and Manickam P. (2002b) Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. Brain Res. Bull. 57, 205-209.
8. Bowden C. L., Janicak P. G., Orsulak P., Swann A. C., Davis J. M., Calabrese J. R., Goodnick P., Small J. G., Rush A. J., Kimmel S. E., Risch S. C. and Morris D. D. (1996) Relation of serum valproate concentration to response in mania. Am. J. Psychiatry 153, 765-770.
9. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
10. Calabrese J. R., Skwerer R. G., Barna B., Gulledge A. D., Valenzuela R., Butkus A., Subichin S. and Krupp N. E. (1986) Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res. 17, 41-47.
11. Chang M. C. and Jones C. R. (1998) Chronic lithium treatment decreases brain phospholipase A2 activity. Neurochem. Res. 23, 887-892.
12. Chang M. C., Grange E., Rabin O., Bell J. M., Allen D. D. and Rapoport S. I. (1996) Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci. Lett. 220, 171-174.
13. Chang M. C., Contreras M. A., Rosenberger T. A., Rintala J. J., Bell J. M. and Rapoport S. I. (2001) Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J. Neurochem. 77, 796-803.
14. Corey E. J., Shih C. and Cashman J. R. (1983) Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc. Natl Acad. Sci. USA 80, 3581-3584.
15. Deutsch J., Rapoport S. I. and Rosenberger T. A. (2003) Valproyl-CoA and esterified valproate are not found in brains of rats treated with valproic acid, but the brain concentrations of CoA and acetyl-CoA are altered. Neurochem. Res. 28, 861-866.
16. 2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J. Biol. Chem. 276, 31720-31731.
17. Feng L., Xia Y., Garcia G. E., Hwang D. and Wilson C. B. (1995) Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J. Clin. Invest. 95, 1669-1675.
18. Fitzpatrick F. A. and Soberman R. (2001) Regulated formation of eicosanoids. J. Clin. Invest. 107, 1347-1351.
19. Frank E., Swartz H. A. and Kupfer D. J. (2000) Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol. Psychiatry 48, 593-604.
20. Guay D. R. (1995) The emerging role of valproate in bipolar disorder and other psychiatric disorders. Pharmacotherapy 15, 631-647.
21. Hayaishi O. (1999) Prostaglandin D2 and sleep - a molecular genetic approach. J. Sleep Res. 8, 60-64.
22. Herschman H. R. (1996) Prostaglandin synthase 2. Biochim. Biophys. Acta 1299, 125-140.
23. Iyer V. G., Reid K. H., Young C., Miller J. and Schurr A. (1995) Early, but not late, antiepileptic treatment reduces relapse of sound-induced seizures in the post-ischemic rat. Brain Res. 689, 159-162.
24. Kam P. C. and See A. U. (2000) Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 55, 442-449.
25. Kaufmann W. E., Worley P. F., Pegg J., Bremer M. and Isakson P. (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl Acad. Sci. USA 93, 2317-2321.
26. Ketterer M. W., Brymer J., Rhoads K., Kraft P. and Lovallo W. R. (1996) Is aspirin, as used for antithrombosis, an emotion-modulating agent? J. Psychosom. Res. 40, 53-58.
27. Kliewer S. A., Umesono K., Noonan D. J., Heyman R. A. and Evans R. M. (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358, 771-774.
28. Lampen A., Siehler S., Ellerbeck U., Gottlicher M. and Nau H. (1999) New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta). Toxicol. Appl. Pharmacol. 160, 238-249.
29. Leonard B. E. (2001) The immune system, depression and the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 767-780.
30. Leslie J. B. and Watkins W. D. (1985) Eicosanoids in the central nervous system. J. Neurosurg. 63, 659-668.
31. Linnoila M., Whorton A. R., Rubinow D. R., Cowdry R. W., Ninan P. T. and Waters R. N. (1983) CSF prostaglandin levels in depressed and schizophrenic patients. Arch. Gen. Psychiatry 40, 405-406.
32. Loscher W. and Honack D. (1995) Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous ('controlled release') administration in a model of generalized seizures in rats. Epilepsia 36, 929-937.
33. Matsumura K., Watanabe Y., Imai-Matsumura K., Connolly M., Koyama Y. and Onoe H. (1992) Mapping of prostaglandin E2 binding sites in rat brain using quantitative autoradiography. Brain Res. 581, 292-298.
34. Mirnikjoo B., Brown S. E., Kim H. F., Marangell L. B., Sweatt J. D. and Weeber E. J. (2001) Protein kinase inhibition by omega-3 fatty acids. J. Biol. Chem. 276, 10888-10896.
35. Nishino S., Ueno R., Ohishi K., Sakai T. and Hayaishi O. (1989) Salivary prostaglandin concentrations: possible state indicators for major depression. Am. J. Psychiatry 146, 365-368.
36. Niwa K., Araki E., Morham S. G., Ross M. E. and Iadecola C. (2000) Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J. Neurosci. 20, 763-770.
37. Noaghiul S. and Hibbeln J. R. (2003) Cross-national comparisons of seafood consumption and rates of bipolar disorder. Am. J. Psychiatry (in press).
38. O'Banion M. K. (1999) Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit. Rev. Neurobiol. 13, 45-82.
39. Parfenova H., Balabanova L. and Leffler C. W. (1998) Posttranslational regulation of cyclooxygenase by tyrosine phosphorylation in cerebral endothelial cells. Am. J. Physiol. 274, C72-C81.
40. Post R. M., Ketter T. A., Denicoff K., Pazzaglia P. J., Leverich G. S., Marangell L. B., Callahan A. M., George M. S. and Frye M. A. (1996) The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl) 128, 115-129.
41. Powell W. S. (1985) Reversed-phase high-pressure liquid chromatography of arachidonic acid metabolites formed by cyclooxygenase and lipoxygenases. Anal. Biochem. 148, 59-69.
42. Rapoport S. I. and Bosetti F. (2002) Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry 59, 592-596.
43. Rapoport S. I., Purdon D., Shetty H. U., Grange E., Smith Q., Jones C. and Chang M. C. (1997) In vivo imaging of fatty acid incorporation into brain to examine signal transduction and neuroplasticity involving phospholipids. Ann. N. Y. Acad. Sci. 820, 56-73; discussion 73-54.
44. Reynolds L. J., Hughes L. L., Yu L. and Dennis E. A. (1994) 1-Hexadecyl-2-arachidonoylthio-2-deoxy-sn-glycero-3-phosphoryl-choline as a substrate for the microtiterplate assay of human cytosolic phospholipase A2. Anal. Biochem. 217, 25-32.
45. Ricote M., Li A. C., Willson T. M., Kelly C. J. and Glass C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
46. Rintala J., Seemann R., Chandrasekaran K., Rosenberger T. A., Chang L., Contreras M. A., Rapoport S. I. and Chang M. C. (1999) 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 10, 3887-3890.
47. Rubin D. and Laposata M. (1992) Cellular interactions between n-6 and n-3 fatty acids: a mass analysis of fatty acid elongation/desaturation, distribution among complex lipids, and conversion to eicosanoids. J. Lipid Res. 33, 1431-1440.
48. Shimizu T. and Wolfe L. S. (1990) Arachidonic acid cascade and signal transduction. J. Neurochem. 55, 1-15.
49. 3H]valproic acid into lipids in GT1-7 neurons. Biochem. Pharmacol. 56, 207-212.
50. Smith W. L., DeWitt D. L. and Garavito R. M. (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182.
51. Stoll A. L., Severus W. E., Freeman M. P., Rueter S., Zboyan H. A., Diamond E., Cress K. K. and Marangell L. B. (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 56, 407-412.
52. Swinney D. C., Mak A. Y., Barnett J. and Ramesha C. S. (1997) Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. J. Biol. Chem. 272, 12393-12398.
53. Szupera Z., Mezei Z., Kis B., Gecse A., Vecsei L. and Telegdy G. (2000) The effects of valproate on the arachidonic acid metabolism of rat brain microvessels and of platelets. Eur. J. Pharmacol. 387, 205-210.
54. Wolfe L. S. and Horrocks L. A. (1994) Eicosanoids, in Basic Neurochemistry (Siegel G. J., Agranoff B. W., Albers R. W. and Molinoff P. B., eds), 5th edn, pp. 475-490. Raven Press, New York.
55. Yamagata K., Andreasson K. I., Kaufmann W. E., Barnes C. A. and Worley P. F. (1993) Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11, 371-386.
56. Yamamoto T. and Nozaki-Taguchi N. (1996) Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor. Brain Res. 739, 104-110.
57. Zarate J. C. A. and Toehn M. (1996) Epidemiology of mood disorders throughout the life cycle, in Mood Disorders Across the Life Span (Shulman K. I., Toehn M. and Kutcher S. P., eds), pp. 17-33. Wiley-Liss, New York.